GENERIC NAME: Nandrolone Phenylpropionate

CHEMICAL NAME: 17β-Hydroxyestra-4-en-3-one 3-phenylpropionate.

MOLECULAR FORMULA: $C_{27}H_{34}O_3$

MOLECULAR WEIGHT: 406.6

DOSAGE FORM: Injection 100mg/ml

COMPOSITION:

NandroRapid® contains a clear oily solution of Nandrolone Phenyl propionate USP (100mg) and Ethyl Oleate NF (Q.S).

PHARMACOLOGICAL CLASSIFICATION:

NandroRapid® is a fast-acting form of Nandrolone. NandroRapid® is a low androgenic steroid with high anabolic effect. It is a derivative of 19-nortestosterone. It works by promoting a positive nitrogen balance in the body that causes the muscles to be able to use more protein, more efficiently than normal. It does this by causing the muscle cells to store more nitrogen than they are releasing. NandroRapid® is a fast acting nandrolone with a shorter active-life of 2-3 days. Water retention with this compound is reported to be less.

In the human, NandroRapid® has been shown to positively influence calcium metabolism and to increase bone mass in osteoporosis. In women with disseminated mammary carcinoma, NandroRapid® has been reported to produce objective regressions for many months. Furthermore, NandroRapid® has a nitrogen-saving action. This effect on protein metabolism has been established by metabolic studies and is utilized therapeutically in conditions where a protein deficiency exists such as during chronic debilitating diseases and after major surgery and severe trauma. In these conditions, nandrolone phenyl propionate serves as a supportive adjunct to specific therapies and dietary measures as well as parenteral nutrition, due to its faster acting nature.

NandroRapid®is used to treat anemia by stimulating red blood cell production and an increase in RBC count can improve endurance during exercise via better lactic acid clearing and oxygen delivery. The blood is also better enabled to carry nutrients to muscle tissue to aid in repair; administration also increases the rate of muscle glycogen repletion.

PHARMACOKINETICS:

The rate of absorption from subcutaneous or intramuscular depots depends on the product and its formulation. The substance Nandrorapid quickly gets into the blood, where it remains active for two



GENERIC NAME: Nandrolone Phenylpropionate

CHEMICAL NAME: 17β-Hydroxyestra-4-en-3-one 3-phenylpropionate.

MOLECULAR FORMULA: $C_{27}H_{34}O_3$

MOLECULAR WEIGHT: 406.6

DOSAGE FORM: Injection 100mg/ml

COMPOSITION:

NandroRapid® contains a clear oily solution of Nandrolone Phenyl propionate USP (100mg) and Ethyl Oleate NF (Q.S).

PHARMACOKINETICS: (Contd.)

to three days. NandroRapid® will aromatise in high dosage. Absorption is slow for the lipid-soluble esters and for oily suspensions. The anabolic steroids are highly protein bound, and is carried in plasma by a specific protein called sex-hormone binding globulin. The metabolism of absorbed drug is rapid, and the elimination half-life from plasma is very short. The duration of the biological effects is therefore determined almost entirely by the rate of absorption from subcutaneous or intramuscular depots, and on the de-esterification which precedes it.

INDICATIONS:

Debilitating illness, postmenopausal osteoporosis, convulsion after surgery, burn or major illness. Postmenopausal metastatic mammary carcinoma.

DOSAGE & ROUTE OF ADMINISTRATION: The dosage is around 100 mg/ml, or a total of 200-400 mg/week. Children 5-15mg every three week. Intra muscular injection is the route of administration.

SIDE EFFECTS:

Oedema, cholestatic jaundice, hepatic carcinoma, gynaecomastia, precocious puberty & shortening of stature due to early closure of epiphysis. Rashes, cramps, dyspepsia. Virilization and menstrual irregularities.

ADVERSE EFFECT:

The adverse effect include weight gain, fluid retention, and abnormal liver function as measured by biochemical tests.Virilization and menstrual irregularities occur in women. Acne and growth disturbances are seen in children. Excessive administration in males may suppress spermatogenesis and cause azoospermia.



GENERIC NAME: Nandrolone Phenylpropionate

CHEMICAL NAME: 17β-Hydroxyestra-4-en-3-one 3-phenylpropionate.

MOLECULAR FORMULA: $C_{27}H_{34}O_3$

MOLECULAR WEIGHT: 406.6

DOSAGE FORM: Injection 100mg/ml

COMPOSITION:

NandroRapid® contains a clear oily solution of Nandrolone Phenyl propionate USP (100mg) and Ethyl Oleate NF (Q.S).

DRUG INTERACTION

Enhances action of oral anticoagulants, corticosteroids.

OVERDOSE:

Acute over dosage can produce nausea and gastrointestinal upset. Chronic usage is thought to cause an increase in muscle bulk, and can cause an exaggeration of male characteristics and effects related to male hormones. Anabolic steroids can influence sexual function. They can also cause cardiovascular and hepatic damage. Acne and male-pattern baldness occur in both sexes; irregular menses, atrophy of the breasts, and clitoromegaly in women; and testicular atrophy and prostatic hypertrophy in men.

PRECAUTIONS:

Diabetes, epilepsy, cardiac disease, prostatic hypertrophy, menstrual irregularities. Also monitor thyroid and liver functions. May alter glucose tolerance test. Watch for oedema and signs of testicular inhibition.

CONTRAINDICATIONS:

Pregnancy or breast-feeding, known or suspected cancer of the prostate or (in men) breast. Nephrotic syndrome, Hepatic impairment, Nephrosis, Porphyria. Known cardiovascular disease is a relative contraindication.

PRESENTATION

5 ampoules of 1ml (100mg/ml) in a plastic tray and such 2 trays in a carton.





GENERIC NAME: Nandrolone Phenylpropionate

CHEMICAL NAME: 17β-Hydroxyestra-4-en-3-one 3-phenylpropionate.

MOLECULAR FORMULA: $C_{27}H_{34}O_3$

MOLECULAR WEIGHT: 406.6

DOSAGE FORM: Injection 100mg/ml

COMPOSITION:

NandroRapid® contains a clear oily solution of Nandrolone Phenyl propionate USP (100mg) and Ethyl Oleate NF (Q.S).

STORAGE:

Stored at room temperature (15 to 30°C). Protect from light. Visual inspection for particulate and/or discoloration is advisable.

MARKETED BY: Alpha-Pharma Healthcare India Pvt. Ltd. A-317, Sagar Tech Plaza Andheri-Kurla Road Sakinaka Junction, Andheri (E) Mumbai-400072, India.

DATE OF PUBLICATION OF THIS PACKAGE INSERT 10th of October 2007

